Table 5.
Multivariable analysis of patient characteristics associated with loss to follow-up during the COVID period.
| Characteristic | Adjusted OR | 97.5% CI | P-value |
|---|---|---|---|
| Age | 0.98 | 0.98–0.99 | <.0001 |
| Female sex | 0.90 | 0.83–0.99 | 0.02 |
| Race | |||
| Native American | 0.58 | 0.15–2.31 | 0.74 |
| Asian | 0.94 | 0.74–1.20 | >0.99 |
| Black or African American | 1.11 | 0.97–1.27 | 0.16 |
| Pacific Islander | 0.65 | 0.33–1.30 | 0.33 |
| Not reported | 1.12 | 0.98–1.27 | 0.11 |
| Preferred language | |||
| Non-English | 1.15 | 0.96–1.37 | 0.15 |
| Unknown | 3.08 | 1.82–5.19 | <.0001 |
| ZIP code AGI per household | 1.00 | 1.00–1.00 | >0.99 |
| Insurance coverage | |||
| Medicaid | 0.78 | 0.68–0.90 | <.0001 |
| Medicare | 0.91 | 0.81–1.03 | 0.20 |
| Unknown | 0.97 | 0.78–1.20 | 0.99 |
| Other | 1.12 | 0.86–1.45 | 0.69 |
| Charlson-Deyo comorbidity index | 0.98 | 0.95–1.01 | 0.20 |
| Pre-COVID period visit diagnosis | |||
| Neoplasms | 0.77 | 0.57–1.05 | 0.11 |
| Endocrine, nutritional and metabolic diseases | 0.90 | 0.69–1.18 | 0.76 |
| Dementia and delirium | 0.81 | 0.65–1.01 | 0.07 |
| Mental (excluding neurodevelopmental) disorders | 0.68 | 0.55–0.85 | <.0001 |
| Neurodevelopmental, behavioral and emotional disorders with childhood/adolescent onset | 0.57 | 0.44–0.73 | <.0001 |
| Systemic atrophies of the CNS | 0.71 | 0.46–1.10 | 0.16 |
| Movement disorders | 0.34 | 0.29–0.40 | <.0001 |
| Demyelinating CNS disorders | 0.18 | 0.15–0.21 | <.0001 |
| Epilepsy | 0.51 | 0.44–0.59 | <.0001 |
| Migraine and other headache disorders | 0.42 | 0.37–0.48 | <.0001 |
| Stroke and cerebrovascular disorders | 1.07 | 0.90–1.26 | 0.75 |
| Sleep disorders | 0.99 | 0.82–1.19 | >0.99 |
| Neuromuscular disorders | 1.02 | 0.88–1.18 | >0.99 |
| Eye, ear, and adnexal disorders | 1.37 | 1.08–1.74 | 0.01 |
| Circulatory disorders | 0.98 | 0.72–1.32 | >0.99 |
| Infectious disorders | 0.77 | 0.54–1.09 | 0.18 |
| Respiratory, digestive, and skin disorders | 0.64 | 0.50–0.81 | <.0001 |
| Musculoskeletal disorders | 0.76 | 0.67–0.87 | <.0001 |
| Abnormal clinical or laboratory findings, not elsewhere classified | 0.76 | 0.65–0.90 | 0.55 |
| Symptoms and signs of nervous and musculoskeletal systems | 0.94 | 0.82–1.07 | 0.01 |
| Symptoms and signs of cognition, perception, emotional state and behavior | 1.25 | 1.04–1.49 | <.0001 |
Regression model references are as follows: White (race); English (preferred language); commercial insurance (insurance coverage).
Model uses imputed race variables.
TN, teleneurology; OR, odds ratio; CI, confidence interval; AGI, adjusted gross income; CNS, central nervous system.